TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28802772

Group type: EXPERIMENTAL
Intervention: Combined exercise training and home-based walking programme
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 52
Study: 27719707

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined triamcinolone acetonide and salvia miltiorrhiza group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OSF group
Number of subjects: 20
Study: 24392848

Group type: EXPERIMENTAL
Intervention: Salmeterol (100 μg twice daily)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 22894553

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg per day)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 20147581

Group type: EXPERIMENTAL
Intervention: NOF guidelines
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: NOGG guidelines
Number of subjects: 1471
Study: 18484588

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Waiting for results of the CT scan
Number of subjects: 351
Study: 15733046

Group type: EXPERIMENTAL
Intervention: Stabilization-enhanced exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: General exercise only
Number of subjects: 55
Study: 12517686

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) infusion
Number of subjects: 21
Study: 10648307

Group type: EXPERIMENTAL
Intervention: Nicardipine (NIC) 30 microg/kg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Esmolol (ESM) 1.0 mg/kg
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Combination (COMB) of NIC and ESM (one-half dose each)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control (CONT) with no pretreatment
Number of subjects: 132
Study: 8646474

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 31
Study: 1644543

Group type: EXPERIMENTAL
Intervention: Semi-open hemorrhoidectomy (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (group B)
Number of subjects: 300
Study: 6496394

Group type: EXPERIMENTAL
Intervention: Normal weight men (fed state)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Obese men (fed state)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal weight men (fasting state)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Obese men (fasting state)
Number of subjects: 12
Study: 30680963

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy after surgical resection
Number of subjects: 162

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 162
Study: 30367804

Group type: EXPERIMENTAL
Intervention: Spiritist 'passe' (SP) sessions for 3 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham sessions for 3 days
Number of subjects: 25
Study: 26244591

Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure (APA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham-Auricular Point Acupressure (sham-APA)
Number of subjects: 61
Study: 25199121

Group type: EXPERIMENTAL
Intervention: 6° head-down tilted bed rest (HDT) for 21 days
Number of subjects: 7
Study: 22244636

Group type: EXPERIMENTAL
Intervention: Patency maintained (PS and PB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No patency (NPS and NPB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Patency maintained in big canals (PB)
Number of subjects: 71
Study: 19935757

Group type: EXPERIMENTAL
Intervention: Cranberry tablets
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cranberry extract tablets
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 17325642

Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Resting (relaxation)
Number of subjects: 44
Study: 16286672

Group type: EXPERIMENTAL
Intervention: HMB/KIC (3 g HMB and 0.3 g alpha-ketoisocaproic acid, daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12000379

Group type: EXPERIMENTAL
Intervention: CDP850 (20 mg kg-1 intravenously as a single dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CDP850
Number of subjects: 13
Study: 9865985

Group type: EXPERIMENTAL
Intervention: Oral cefixime 200 mg combined with probenecid 500 mg three times daily for 100 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 2 g daily for 14 days followed by oral amoxicillin 500 mg combined with probenecid 500 mg three times daily for 100 days
Number of subjects: 60
Study: 7869937

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 32
Study: 2803397

Group type: EXPERIMENTAL
Intervention: Group 1: Halothane anaesthesia and retroauricular infiltration anaesthesia with lidocaine and ornipressin (n = 14)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group 2: Fentanyl anaesthesia and retroauricular anaesthesia with lidocaine and ornipressin (n = 10)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group 3: Fentanyl anaesthesia and retroauricular infiltration anaesthesia with lidocaine and epinephrine (n = 14)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Group 4: Retroauricular infiltration anaesthesia with prilocaine and epinephrine (n = 14)
Number of subjects: 49
Study: 809253

Group type: EXPERIMENTAL
Intervention: Oral TRH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous TRH
Number of subjects: 0
Study: 30961412

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (TSST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (P-TSST)
Number of subjects: 32
Study: 27826874

Group type: EXPERIMENTAL
Intervention: 3-day aprepitant regimen on top of ondansetron plus dexamethasone
Number of subjects: 494

Group type: COMPARATOR
Intervention: Placebo (control regimen) on top of ondansetron plus dexamethasone
Number of subjects: 494
Study: 25307195

Group type: EXPERIMENTAL
Intervention: Promotora-led lifestyle behavior intervention (group education and individual coaching)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Promotora-led lifestyle behavior intervention
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group (comparable length educational program)
Number of subjects: 223
Study: 22617866

Group type: EXPERIMENTAL
Intervention: Active Neurofeedback (NF)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham Neurofeedback (sham-NF)
Number of subjects: 39
Study: 17034515

Group type: EXPERIMENTAL
Intervention: Increased sebum output level
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ovulation phase
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Severity of acne
Number of subjects: 60
Study: 12884360

Group type: EXPERIMENTAL
Intervention: Altered lipid diets (fish oil supplement or seafood diet)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Altered lipid diets (Lorenzo's oil diet)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal lipid composition
Number of subjects: 25
Study: 10833208

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg intramuscularly once weekly for 40 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo for 40 weeks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg intramuscularly once weekly
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 8799522

Group type: EXPERIMENTAL
Intervention: Activation of rigidity measured by torque required to move the forearm
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Work required under activation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Work ratio in spouses of parkinsonians
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sinemet CR (levodopa 200 mg/carbidopa 50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sinemet-Plus (levodopa 100 mg/carbidopa 25 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Benzhexol (2 mg tablets)
Number of subjects: 20
Study: 1483496

Group type: EXPERIMENTAL
Intervention: Oral famotidine (40 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (20 mg)
Number of subjects: 16
Study: 6397847

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 31037285

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg intravitreous injection every 4 weeks)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 702

Group type: COMPARATOR
Intervention: Aflibercept vs Laser photocoagulation
Number of subjects: 702

Group type: COMPARATOR
Intervention: Aflibercept vs Observation
Number of subjects: 702

Group type: COMPARATOR
Intervention: Laser photocoagulation vs Observation
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 702
Study: 27977439

Group type: EXPERIMENTAL
Intervention: Bilateral sternal infusion of 0.2% ropivacaine (3 ml/h through each catheter)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standardised care only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bilateral sternal infusion of 0.2% ropivacaine
Number of subjects: 120
Study: 26376830

Group type: EXPERIMENTAL
Intervention: Usual pharmacy services plus pharmacist interventions based on shared decision making
Number of subjects: 239

Group type: COMPARATOR
Intervention: Usual pharmacy services
Number of subjects: 239
Study: 24107474

Group type: EXPERIMENTAL
Intervention: Volume-targeted ventilation (VTV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pressure-limited ventilation (PLV)
Number of subjects: 40
Study: 21127013

Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nicotine
Number of subjects: 10
Study: 19709377

Group type: EXPERIMENTAL
Intervention: Acupuncture at points LI‐4 (he gu) and HT‐7 (shen men) immediately after induction of anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study: 18575355

Group type: EXPERIMENTAL
Intervention: Specific treatment (computer cognitive rehabilitation) consisting of 12 individual sessions of computer exercises
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control condition (aspecific treatment) consisting of semi-structured interviews with patients
Number of subjects: 11
Study: 15154946

Group type: EXPERIMENTAL
Intervention: Specialist nurse-led educational outreach for hyperlipidaemia
Number of subjects: 10303

Group type: EXPERIMENTAL
Intervention: Specialist nurse-led educational outreach for hypertension
Number of subjects: 10303

Group type: EXPERIMENTAL
Intervention: Overall specialist nurse-led educational outreach
Number of subjects: 10303
Study: 11421962

Group type: EXPERIMENTAL
Intervention: Tier one of the Three Tiered Plan intervention implemented in 1998
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Post-implementation feedback from interns
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Self-reported knowledge of indigenous health and culture by interns
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Perception of the intervention by indigenous hospital liaison officers
Number of subjects: 43
Study: 9780015

Group type: EXPERIMENTAL
Intervention: Vanillin at 7% v/v
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vanillin at 28% v/v
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vanillin at 56% v/v
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vanillin at 84% v/v
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Increasing concentrations of vanillin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: OERP latencies
Number of subjects: 16
Study: 3183034

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon administered daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal controls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (other medical disease - OMD)
Number of subjects: 0
Study: 31615466

Group type: EXPERIMENTAL
Intervention: Sequential HAIC with cisplatin followed by sorafenib
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 68
Study: 27671836

Group type: EXPERIMENTAL
Intervention: 2-hourly feeding
Number of subjects: 150

Group type: COMPARATOR
Intervention: 3-hourly feeding
Number of subjects: 150
Study: 25217501

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 3102

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 3102
Study: 23963102

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day plus Tolterodine 2 mg (twice a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine 2 mg (twice a day)
Number of subjects: 0
Study: 21412090

Group type: EXPERIMENTAL
Intervention: iohexol 350
Number of subjects: 100

Group type: COMPARATOR
Intervention: meglumine sodium diatrizoate
Number of subjects: 100
Study: 19170139

Group type: EXPERIMENTAL
Intervention: Pomegranate extract mouth rinsing (PomElla)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (cornstarch in water)
Number of subjects: 32
Study: 17022370

Group type: EXPERIMENTAL
Intervention: Glide dental floss
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Butler flossers
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: GUM Go‐Betweens cleaners
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: GUM Soft‐Picks cleaners
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 120
Study: 14752120

Group type: EXPERIMENTAL
Intervention: Hokanson system (HEC4)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Filtrass 2001 system (F2001)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Stroop's colored word conflict test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postocclusive hyperemia after occlusion times of 5 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postocclusive hyperemia after occlusion times of 8 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postocclusive hyperemia after occlusion times of 13 min
Number of subjects: 10
Study: 11097146

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 100 mg twice daily for one week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 10
Study: 9067912

Group type: EXPERIMENTAL
Intervention: Atenolol or Enalapril
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment after 4 years
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group A (N = 20) with largest initial treatment-induced fall in GFR
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment in Group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Withdrawal of treatment in Group B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-treatment GFR in Group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-treatment GFR in Group B
Number of subjects: 40
Study: 8446039

Group type: EXPERIMENTAL
Intervention: Dairy butter (B) diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Soybean oil (SO) diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Olive oil (OO) diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cocoa butter (CB) diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Milk chocolate (C) diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cocoa butter + dairy butter (CB+B) diet (4:1, MIX)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Plasma very-low density lipoprotein (VLDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and apo A-I levels
Number of subjects: 33
Study: 3716914

Group type: EXPERIMENTAL
Intervention: Cigarette smoking and caffeine administration during task performance
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Task performance
Number of subjects: 9
Study: 29699979

Group type: EXPERIMENTAL
Intervention: Targeted retinal photocoagulation (TRP)
Number of subjects: 24
Study: 27321608

Group type: EXPERIMENTAL
Intervention: Vision-based speed-of-processing (VSOP) training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mental leisure activities (MLA)
Number of subjects: 21
Study: 24720741

Group type: EXPERIMENTAL
Intervention: Injection of 1600 µl
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Injection of 1200 µl
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Thigh injections
Number of subjects: 82
Study: 22555227

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19699488

Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160mg/d)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 18605811

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 173

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 173
Study: 15620501

Group type: EXPERIMENTAL
Intervention: Vicryl Rapide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vicryl
Number of subjects: 60
Study: 11836328

Group type: EXPERIMENTAL
Intervention: High-dose testosterone (200 mg) in older men
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low-dose testosterone (100 mg) in young men
Number of subjects: 68

Group type: COMPARATOR
Intervention: Saline (control) in older men
Number of subjects: 68
Study: 10392872

Group type: EXPERIMENTAL
Intervention: Suture-mediated closure device
Number of subjects: 600

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 600
Study: 8907566

Group type: EXPERIMENTAL
Intervention: Alpha-interferon treatment
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control (non-responders)
Number of subjects: 347
Study: 1919966

Group type: EXPERIMENTAL
Intervention: Prism adaptation preoperative treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prism adaptation
Number of subjects: 0
Study: 7128838

Group type: EXPERIMENTAL
Intervention: Danazol (800 mg daily for the first 2 months, 600 mg daily for the next 2 months, and 400 mg daily for the final 2 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No treatment for 6 months
Number of subjects: 65
Study: 31883123

Group type: EXPERIMENTAL
Intervention: Estimand framework
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional intention-to-treat or per protocol analysis
Number of subjects: 0
Study: 30966821

Group type: EXPERIMENTAL
Intervention: Traditional risk assessment (arm A)
Number of subjects: 43447

Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (arm B)
Number of subjects: 43447

Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 43447
Study: 28455814

Group type: EXPERIMENTAL
Intervention: Strength training at 80% of 1‐repetition maximum (1‐RM) for 3 weeks
Number of subjects: 20
Study: 25493927

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (group D)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 0.9% saline (group C)
Number of subjects: 46
Study: 23684375

Group type: EXPERIMENTAL
Intervention: Multimedia based health information
Number of subjects: 101

Group type: COMPARATOR
Intervention: Verbal health information
Number of subjects: 101
Study: 21461323

Group type: EXPERIMENTAL
Intervention: Algorithmic internet-based intervention alone
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Algorithmic internet-based intervention with prescribed bedtime routine
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (usual routine)
Number of subjects: 264
Study: 18339412

Group type: EXPERIMENTAL
Intervention: Focused instruction during a 4‐h training session
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard written instructions in PIM application
Number of subjects: 40
Study: 16433714

Group type: EXPERIMENTAL
Intervention: Professional-directed implementation programme
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patient-centred implementation programme
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (usual hospital outpatient care)
Number of subjects: 13
Study: 12036483

Group type: EXPERIMENTAL
Intervention: ART plus CTX
Number of subjects: 10

Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 10
Study: 10213347

Group type: EXPERIMENTAL
Intervention: Glimepiride (1.162 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glibenclamide (2.54 mg)
Number of subjects: 45
Study: 7840072

Group type: EXPERIMENTAL
Intervention: Boron supplementation
Number of subjects: 0
Study: 2400038

Group type: EXPERIMENTAL
Intervention: Admissions attended by physicians licensed for more than 15 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Admissions attended by younger physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 0
Study: 14317

Group type: EXPERIMENTAL
Intervention: FC 35aA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dipotassic chlorazepate, paracetamol and codeine (individual components)
Number of subjects: 30
Study: 6948502

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31305927

Group type: EXPERIMENTAL
Intervention: High energy turnover (ET)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low energy turnover (ET)
Number of subjects: 16
Study: 29510857

Group type: EXPERIMENTAL
Intervention: Elbow flexed (EF) crutch setup
Number of subjects: 30

Group type: COMPARATOR
Intervention: Elbow extended (EE) crutch setup
Number of subjects: 30